ArticleCureus2025
Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNis) in High-Output Heart Failure in a Young Hemodialysis Patient: Synergistic or Cumulative Effect?
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In hemodialysis patients, an arteriovenous fistula (AVF) is the preferred option for vascular access. High-output heart failure (HOHF) due to a high-flow AVF can be an underrecognized complication, and arterial hypertension is among the most prevalent comorbidities in this population. Consequently, these patients are closely monitored during hemodialysis and routinely evaluated for cardiovascular pathology. A 32-year-old woman on hemodialysis for five years presented with hypertension refractory to triple pharmacologic therapy and dialysis, pleural effusion, exertional dyspnea, peripheral edema, and jugular venous distention. She was evaluated at an internal medicine day hospital to investigate the underlying cause of recurrent pleural effusion. She was found to have a concomitant high-flow AVF (Qa >3000 mL/min), which had undergone multiple banding procedures. Thoracentesis with cytobiochemical analysis revealed a transudative pleural effusion. Transthoracic echocardiography (TTE) demonstrated HF with reduced ejection fraction (38%) and pulmonary artery systolic pressure (PASP) of 46 mmHg; N-terminal pro-BNP (NT-proBNP) was 113,883 pg/mL. After multidisciplinary discussion, all antihypertensive therapy was replaced with intermediate-dose sacubitril/valsartan (SAC/VAL), aiming to control blood pressure and improve ejection fraction, with close monitoring of serum potassium and hemodynamics. Within two weeks, blood pressure control and symptoms improved significantly, with resolution of the pleural effusion. Two months after initiating SAC/VAL, the AVF was surgically closed, and dialysis access was switched to a long-term catheter. At six-month follow-up, repeat TTE showed recovery of ejection fraction to 71% and reduction of PASP to 23 mmHg. NT-proBNP decreased to 2,005 pg/mL, corroborating clinical improvement. The patient remains clinically stable. Continuous clinical assessment and individualized management are essential for addressing complex conditions in dialysis patients. Further research is warranted to establish the efficacy and safety of SAC/VAL in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.